RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis study tests a new drug (seclidemstat) combined with a standard drug (azacitidine) for people with myelodysplastic syndromes or chronic myelomonocytic leukemia. The goal is to find the best dose and see if the combo can shrink or control the cancer. About 24 adults with these…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
New drug combo shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and azacitidine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to standard therapy. The goal is to find the best dose and see how well th…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new antibody called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goal is to find a safe dose and check for side effects. Researchers hope the antibody can slow or stop cancer growth.
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New drug combo targets Hard-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, azacitidine and quizartinib, in 30 adults with certain blood cancers (MDS, MDS/MPN, CMML) that have specific gene mutations (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the cancer. This is not a c…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC